Local Tech Wire
RESEARCH TRIANGLE PARK, N.C. – , which is developing a form of dried human blood plasma for use in transfusions, has won a two-year research and development contract worth $8.2 million from the Pentagon.
The Department of Defense worked with Entegrion earlier on a feasibility analysis.
“This technology will help improve the safety and availability of blood and blood products for transfusion in domestic and global health applications, and we are pleased to see the military’s continued confidence and investment commitment to the technology,” said Joseph DaCorta, Entegrion’s chief technology officer, in a statement.
“The dried human plasma uses a technology that overcomes the normal limitation of shelf-life and refrigeration storage requirements of blood products,” he added. “Such benefits are important to both civilian and military medical operations, especially in remote areas.”
The company plans to use the funds to prepare for production and manufacturing of the product as well as clinical development.
Entegrion is also developing gels and sprays for use in tissue repair, products to control internal hemorrhage and means of targeted drug delivery to tumors and sites of internal bleeding.
Get the latest news alerts: at Twitter.
